Image: Wikimedia Commons UK researchers are rushing to develop a new Ebola vaccine based on the exact same viral vector platform used in the Oxford/AstraZeneca COVID-19 jab. The effort comes as a new outbreak of the Bundibugyo strain of Ebola continues to spread in the Democratic Republic of Congo. The Oxford Vaccine Group (OVG) announced it is urgently producing its candidate vaccine, ChAdOx1 BDBV, which could enter human clinical trials in as little as two to three months if animal testing succeeds. The Bundibugyo Ebolavirus is one of the less common but still highly lethal strains of Ebola. Unlike the more frequently seen Zaire strain, there are currently no licensed vaccines or specific treatments approved for Bundibugyo virus disease. The WHO and local authorities have…
Click here to read the full article at The Gateway Pundit.
